Design Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Design Therapeutics

04/11/2022 14:05

* Design Therapeutics Inc  DSGN.OQ   DSGN.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 7 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Design Therapeutics
Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Design
Therapeutics Inc is $29​, above​ its last closing price
of $15.49. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.25       -0.25      -0.27     Missed  -8
 Mar. 31 2022  -0.22       -0.22      -0.24     Missed  -9.1
 Dec. 31 2021  -0.25       -0.23      -0.20     Beat    11.8​
 Sep. 30 2021  -0.14       -0.14      -0.21     Missed  -50
 ​​Jun.        -0.18       -0.18      -0.14     Beat    23.6
 30 2021                                                
 Mar. 31 2021  -0.07       -0.07      -0.31     Missed  -322.7
                                                        ​
 This summary was machine generated November 4 at 14:05 GMT.  All
figures in US dollars  unless otherwise stated